lncRNA GAS6-AS1 inhibits progression and glucose metabolism reprogramming in LUAD via repressing E2F1-mediated
Jing Luo1,2, Huishan Wang3, Li Wang4
1Department of Thoracic Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Jiangsu Key Laboratory of Molecular and Translational Cancer Research, Nanjing 210000, China.
Abstract:
Glucose metabolism reprogramming is one of the hallmarks of cancer cells, although functional and regulatory mechanisms of long noncoding RNA (lncRNA) in the contribution of glucose metabolism in lung adenocarcinoma (LUAD) remain incompletely understood. The aim of this study was to uncover the role of GAS6-AS1 in the regulation of progression and glucose metabolism in LUAD. We discovered that overexpression of GAS6-AS1 suppressed tumor progression of LUAD both in vitro and in vivo. Metabolism-related assays revealed that GAS6-AS1 inhibited glucose metabolism reprogramming. Mechanically, GAS6-AS1 was found to repress the expression of glucose transporter GLUT1, a key regulator of glucose metabolism. Ectopic expression of GLUT1 restored the inhibition effect of GAS6-AS1 on cancer progression and glucose metabolism reprogramming. Further investigation identified that GAS6-AS1 directly interacted with transcription factor E2F1 and suppressed E2F1-mediated transcription of GLUT1, and GAS6-AS1 was downregulated in LUAD tissues and correlated with clinicopathological characteristics and survival of patients. Taken together, our results identified GAS6-AS1 as a novel tumor suppressor in LUAD and unraveled its underlying molecular mechanism in reprogramming glucose metabolism. GAS6-AS1 potentially may serve as a prognostic marker and therapeutic target in LUAD.
Insights
Long noncoding RNA GAS6-AS1 suppresses lung adenocarcinoma (LUAD) progression by inhibiting glucose metabolism. GAS6-AS1 acts as a tumor suppressor, potentially serving as a therapeutic target for LUAD.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Glucose metabolism reprogramming is a hallmark of cancer.
- The role of long noncoding RNAs (lncRNAs) in lung adenocarcinoma (LUAD) glucose metabolism is not fully understood.
Purpose of the Study:
- To investigate the function of GAS6-AS1 in LUAD progression and glucose metabolism.
- To elucidate the molecular mechanisms underlying GAS6-AS1's role in LUAD.
Main Methods:
- In vitro and in vivo experiments to assess tumor progression.
- Metabolism-related assays to analyze glucose metabolism.
- Western blotting and qRT-PCR to examine gene expression.
- RNA immunoprecipitation and luciferase reporter assays to determine molecular interactions.
Main Results:
- Overexpression of GAS6-AS1 suppressed LUAD progression and inhibited glucose metabolism.
- GAS6-AS1 repressed GLUT1 expression by interacting with E2F1, suppressing GLUT1 transcription.
- GAS6-AS1 was downregulated in LUAD tissues and correlated with poor prognosis.
Conclusions:
- GAS6-AS1 acts as a tumor suppressor in LUAD by inhibiting glucose metabolism reprogramming.
- GAS6-AS1 may serve as a prognostic biomarker and therapeutic target for LUAD.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
Cell Specific Gene Expression
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs

